SEPTEMBER 18, 2018
By GREGORY ZELLER
A Stony Brook biotech with a growing international reputation for supply-chain security has spun off a new company focused on DNA modification and production.
With an eye on exploding biotherapeutic fields, Stony Brook-based Applied DNA Sciences has spun its DNA-manufacturing business into a new company, LineaRx.
Stony Brook-based Applied DNA Sciences on Tuesday announced the formation of LineaRx Inc., a wholly owned subsidiary that will concentrate on commercializing the parent company’s extensive experience in the design, manufacture and chemical modification of DNA by large-scale polymerase chain reaction – big news for scientists working on new vaccines, cellular therapies and other advances in burgeoning biotherapeutics fields.
